KYMERA THERAPEUTICS I
43.04
08-October-24 15:59:58
15 minutes delayed
Stocks
+0.83
+1.97%
Today's range
42.41 - 43.90
ISIN
N/A
Source
NASDAQ
-
29 Jul 2021 07:00:02 By Nasdaq GlobeNewswire
-
06 Jul 2021 16:00:00 By Nasdaq GlobeNewswire
-
Kymera Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
30 Jun 2021 21:45:35 By Nasdaq GlobeNewswire
-
Kymera Therapeutics Announces Proposed Public Offering of Common Stock
28 Jun 2021 16:36:38 By Nasdaq GlobeNewswire
-
28 Jun 2021 06:00:00 By Nasdaq GlobeNewswire
-
Kymera Therapeutics Appoints Elaine Caughey, MBA, as Chief Business Officer
21 Jun 2021 16:00:00 By Nasdaq GlobeNewswire
-
Kymera Therapeutics to Participate in Goldman Sachs 42nd Annual Global Healthcare Conference
02 Jun 2021 16:00:00 By Nasdaq GlobeNewswire
-
26 May 2021 09:00:00 By Nasdaq GlobeNewswire
-
10 May 2021 09:00:00 By Nasdaq GlobeNewswire
-
Kymera Therapeutics Announces First Quarter 2021 Financial Results and Provides a Business Update
06 May 2021 07:00:01 By Nasdaq GlobeNewswire
-
Kymera Therapeutics Appoints Juliet Williams, PhD, as Senior Vice President, Head of Biology
05 May 2021 07:00:01 By Nasdaq GlobeNewswire
-
Kymera Therapeutics to Present at Upcoming May Investor Conferences
04 May 2021 07:00:02 By Nasdaq GlobeNewswire
-
03 May 2021 16:00:40 By Nasdaq GlobeNewswire
-
Kymera Therapeutics Honored by Boston Business Journal as a 2021 Best Places to Work Company
19 Apr 2021 07:30:00 By Nasdaq GlobeNewswire
-
10 Apr 2021 08:30:00 By Nasdaq GlobeNewswire